Last edition
News about
GSK Secures FDA Approval for Lynavoy, First Treatment for PBC-Related Chronic Itch
FDA approves GSK’s Lynavoy (linerixibat), the first therapy for cholestatic pruritus in primary biliary cholangitis patients, offering significant and sustained itch relief.
Earendil Labs Raises USD 787 Million to Scale AI-Driven Biologics Discovery
Earendil Labs will use its USD 787 million financing to scale its Artificial Intelligence (AI)-driven R&D platform, expand inter-disciplinary teams and advance a pipeline of antibody and biologics programmes targeting serious diseases.
IntraBio Submits sNDA for Levacetylleucine in Ataxia-Telangiectasia
IntraBio has submitted an sNDA to the US Food and Drug Administration (FDA) for Levacetylleucine, marking the first regulatory filing seeking approval for the treatment of Ataxia-Telangiectasia.
Eris Lifesciences Launches Weekly Semaglutide Shot at INR 220 in India
Eris Lifesciences has launched a weekly Semaglutide injection starting at INR 220 per dose and plans to introduce a pen-device version in April, priced between INR 4,000 and INR 4,500 per month to enhance patient convenience and adoption.
MiniMed Gets FDA Clearance for Smartphone-Controlled Insulin Pump Flex
MiniMed has received clearance from the US Food and Drug Administration (FDA) for its latest insulin delivery device, MiniMed Flex. The new system is a compact, smartphone-controlled insulin pump designed to make diabetes management less visible and easier to handle in everyday life.
Zydus Lifesciences Launches Aerolife Mini, India's First Portable Foldable Spacer
Zydus introduces Aerolife Mini, a compact pMDI enhancer designed to improve inhaler drug delivery and patient compliance in respiratory care through a convenient, foldable design.
Glenmark Pharma USA Launches Generic Milnacipran Tablets
Glenmark Pharmaceuticals USA has launched Milnacipran Hydrochloride tablets in multiple strengths as the authorised generic of Savella, expanding treatment access in the US market.
Johnson & Johnson Secures FDA Approval for Icotyde, First Oral IL-23 Inhibitor for Psoriasis
FDA approves Johnson & Johnson’s Icotyde, a first-in-class oral IL-23 receptor antagonist, offering a once-daily treatment option for moderate-to-severe plaque psoriasis in adults and adolescents.
Natco to Launch Semaglutide Generic at 90 Percent Discount in India
Natco Pharma is set to launch a generic version of semaglutide in India at a sharply reduced price, signalling the start of an intense price competition in the diabetes and weight-loss drug segment.
Illumina, Labcorp Expand Partnership to Advance Precision Oncology
Illumina and Labcorp have expanded their collaboration to strengthen precision oncology through wider use of next-generation sequencing (NGS) technologies.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy